Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts. 

Market Access Risk Assessment Company - MARA Rating Company

Market access risk in infectious diseases

Infectious disease is the field where the usual rules of reimbursement bend. Governments buy antivirals and vaccines in bulk during an epidemic and then hand them to insurers when it ends; antibiotics are most valuable when they are not used, which punishes them under any system that pays per prescription; and prevention asks a payer to fund infections that will never happen, in people who may or may not take the drug. Each of those twists has produced its own reimbursement machinery — stockpiles, subscription contracts, risk-group eligibility — and a new drug meets one of them rather than the ordinary route. This page brings together MARA's independent assessments of reimbursement risk across the field.

What payers ask in infectious diseases

Who is the payer, this year? A pandemic antiviral bought by governments at a single negotiated price becomes, after the emergency, a drug that insurers assess like any other — with a different population, a different comparator and a different willingness to pay. The route a drug takes to the patient can change within its own launch year.

How is a drug paid for when the goal is to use it rarely? A new antibiotic earns its value by being held in reserve against resistant infections. Under per-prescription reimbursement that value is invisible, so payers have begun experimenting with subscription payments and stewardship-linked contracts — and a new antibiotic's commercial life depends on which model its market has adopted.

How do you count an infection that did not happen? For prophylaxis and pre-exposure prevention the benefit is an absence. Payers ask how large the risk was in the people treated, how faithfully they took the drug in practice, and what the system would have spent on the infections avoided — the answer narrows eligibility to the groups where the arithmetic holds.

Will the evidence still fit the virus at launch? Trials in fast-moving epidemics are run against one variant and read by payers facing another, on endpoints — viral load, symptom days — that may not match the hospitalisations the payer wants to prevent. The gap between trial conditions and the season of launch is a reimbursement risk of its own.

The MARA record in infectious diseases

Infectious diseases holds fourteen dated assessments in the MARA catalogue: COVID-19 treatment and prophylaxis, combination respiratory vaccines, new oral antibiotics for urinary infection and gonorrhoea, HIV prevention, influenza prophylaxis, cytomegalovirus after transplant and herpes in the immunocompromised. Each report answers the same payer questions, carries its "as of" date, and stays on the record — when the evidence moves, a newer vintage replaces the older one visibly, never silently. Assessments are produced on MARA's own initiative for awareness; the current MARA Rating for any drug is available on request.

Current assessments (13)

Earlier assessments (each replaced by a newer version)

Selected commentary

For how a MARA Rating is built, see the methodology and what a MARA Rating is. To request the current rating for any drug in this area, use the contact form.